Drug combination improves progression-free survival in melanoma patients

Patients with advanced melanoma skin cancer survive for longer without their disease progressing if they have been treated with a combination of two drugs, nivolumab and ipilimumab, than with either of these drugs alone. New results show that these patients also do better regardless of their age, stage of disease and whether or not they have a cancer-driving mutation in the BRAF gene.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1LfSIm4